欧美精品v国产精品v日韩精品,第一次处破女太舒服了,色婷婷久久久swag精品,A片在线观看免费视频,√最新版天堂资源网在线

通化东宝2024年度(du)业绩预告：上半(ban)年业绩受非经常性因素冲击 下半(ban)年集采推(tui)动(dong)门冬销(xiao)量增长超300%

  2025年(nian)(nian)(nian)1月20日，通(tong)化东宝(bao)药业(ye)(ye)股份(fen)有限公(gong)(gong)(gong)司(si)（以(yi)下简称“通(tong)化东宝(bao)”或(huo)“公(gong)(gong)(gong)司(si)”）发布2024年(nian)(nian)(nian)年(nian)(nian)(nian)度业(ye)(ye)绩预减(jian)公(gong)(gong)(gong)告(gao)。2024年(nian)(nian)(nian)，公(gong)(gong)(gong)司(si)预计实现归属于上市公(gong)(gong)(gong)司(si)股东的净利润约0.41亿(yi)元，同比减(jian)少(shao)96.53%；归属于上市公(gong)(gong)(gong)司(si)股东的扣除...

通化东宝(bao)：依托(tuo)考昔(xi)片(pian)获得上市(shi)许可，痛风领域商(shang)业化在即

通(tong)化东宝药(yao)(yao)业(ye)股份有限公(gong)(gong)司(si)(si)（以(yi)下简称“公(gong)(gong)司(si)(si)”或“通(tong)化东宝”）于近日(ri)收到国家药(yao)(yao)品监督管理局核准签发的依(yi)托考(kao)昔片(pian)《药(yao)(yao)品注(zhu)册(ce)证书(shu)》，意味着公(gong)(gong)司(si)(si)在痛(tong)风领域(yu)商业(ye)化的临(lin)近。 依(yi)托考(kao)昔片(pian)获得(de)上(shang)市许可，标志着通(tong)化...

通(tong)化东宝：GLP-1/GIP双靶点受(shou)体(ti)激动剂（注射用(yong)THDBH120）减重适(shi)应症(zheng)II期(qi)临床试验(yan)完成首例受(shou)试者给药

通(tong)化东(dong)宝(bao)药(yao)业(ye)股份有(you)限公(gong)司(si)（以下简称(cheng)“通(tong)化东(dong)宝(bao)”、“公(gong)司(si)”）全资(zi)子公(gong)司(si)东(dong)宝(bao)紫星（杭州）生物医药(yao)有(you)限公(gong)司(si)取得国家药(yao)品监督管理局(ju)药(yao)品审评中(zhong)心（CDE）签(qian)发的关于注射用THDBH120减(jian)重适(shi)应症(zheng)药(yao)物临床试验批(pi)准通(tong)知书后...

通化东(dong)宝：GLP-1/GIP双靶点受体激动剂（注射用THDBH120）获得Ia期临床试验(yan)总结报告

通化(hua)东(dong)宝药(yao)(yao)业股份有(you)限(xian)(xian)公(gong)司(si)（以下(xia)简(jian)(jian)称“公(gong)司(si)”）全资子(zi)公(gong)司(si)东(dong)宝紫(zi)星(xing)（杭州(zhou)）生物医药(yao)(yao)有(you)限(xian)(xian)公(gong)司(si)（以下(xia)简(jian)(jian)称“东(dong)宝紫(zi)星(xing)”）获得注(zhu)射用(yong)THDBH120药(yao)(yao)物临(lin)床试验批准后，根据国内(nei)化(hua)学药(yao)(yao)品创新药(yao)(yao)相(xiang)关指导原则，近日完成了一项“...

通化东宝药业股份有限公司(si)关于竞争(zheng)性谈判选聘2024年(nian)度会(hui)计师事(shi)务所的(de)公告(gao)

通(tong)(tong)化(hua)东宝药业(ye)(ye)股(gu)份有限公司关(guan)于竞争性谈(tan)判(pan)选聘(pin)2024年度会计(ji)师事务所(suo)的公告 根据财政部(bu)《国有企(qi)业(ye)(ye)、上市(shi)公司选聘(pin)会计(ji)师事务所(suo)管(guan)理办法(fa)》【财会〔2023〕4号(hao)】等有关(guan)规定，通(tong)(tong)化(hua)东宝药业(ye)(ye)股(gu)份有限公司（以下简称“公司”、...

通化东(dong)宝：德谷胰岛素利拉鲁肽注(zhu)射液Ⅰ期(qi)临床试验完成总结报告

2024年(nian)11月8日，通化东(dong)宝(bao)药(yao)(yao)业股份(fen)有限公(gong)司（以下简称“通化东(dong)宝(bao)”或“公(gong)司”）收到国家药(yao)(yao)品监督管理局(ju)签发的关于(yu)德谷(gu)胰岛(dao)素利拉(la)鲁肽注(zhu)射液(ye)药(yao)(yao)物(wu)临(lin)床(chuang)试(shi)验(yan)批准通知书后，已经完成了(le)一项关键I期临(lin)床(chuang)试(shi)验(yan)并(bing)获得临(lin)床(chuang)试(shi)验(yan)总...